The 13th International Conference on Malignant Lymphoma took place June 17-20, 2015, in Lugano, Switzerland.

Novel mAb targeting CD70 shows activity in TCL

Print Friendly, PDF & Email


monoclonal_antibodies_growing_Credit_Linda_Bartlett_230.jpg
Growing monoclonal antibodies
Photo by Linda Bartlett

The defucosylated monoclonal antibody (mAb) ARGX-110, which is active against CD70-bearing tumor cells and CD70-dependent stimulation of regulatory T cells, has shown activity in relapsed/refractory T-cell lymphoma (TCL), according to investigators. Of the 8 TCL patients enrolled in a phase 1 trial of ARGX-110, 3 had a... [Read Article]

Print Friendly, PDF & Email

Novel SYK inhibitor shows ‘good early evidence’ of activity

Print Friendly, PDF & Email


dlbcl_wiki_240.jpg
Micrograph showing DLBCL

The phase 1, first-in-human study of the novel SYK inhibitor TAK-659 is showing “good early evidence” of antitumor activity in patients with lymphoma, according to investigators. The agent also appears to be fairly well tolerated, with 10 categories of adverse events occurring in 2 or more patients. Adam M. Petrich, MD, of... [Read Article]

Print Friendly, PDF & Email

Team endorses intensified chemo for PET-positive HL

Print Friendly, PDF & Email


young_adult_pt_receiving_chemo_Credit_Rhoda_Baer_230.jpg
Patient receives chemotherapy
Photo by Rhoda Baer

Long-awaited results of the Intergroup H10 trial in PET-positive Hodgkin lymphoma (HL) patients have shown that intensifying chemotherapy significantly increases 5-year progression-free survival (PFS) and produces a non-significant increase in overall survival (OS). Switching patients who are PET-positive after 2 cycles of ABVD to escalated BEACOPP... [Read Article]

Print Friendly, PDF & Email

‘Radically different’ PI3Kδ inhibitor lacks hepatotoxicity

Print Friendly, PDF & Email


oconnor-owen-tclf14-larry-young_230_brt.jpg
Owen O’Connor, MD, PhD
Photo by Larry Young

Updated phase 1 results with TGR-1202 suggest this next-generation PI3kδ inhibitor lacks the hepatotoxicity associated with other PI3Kδ inhibitors. Investigators also confirmed that no case of colitis has been reported to date with TGR-1202, and only 2% of evaluable patients on this trial have experienced... [Read Article]

Print Friendly, PDF & Email

Nivolumab produces ‘dramatic’ responses in HL

Print Friendly, PDF & Email


timmerman-john-ucla-230.jpg
John Timmerman, MD
Photo courtesy of UCLA

The PD-1 checkpoint inhibitor nivolumab produces rapid, durable, and, in some cases, “dramatic” responses in Hodgkin lymphoma (HL), according to a speaker at the 13th International Congress on Malignant Lymphoma. The drug has also produced durable responses in follicular lymphoma (FL), cutaneous T-cell lymphoma (CTCL), and peripheral... [Read Article]

Print Friendly, PDF & Email

Targeted agent shows early promise for NHL

Print Friendly, PDF & Email


follicular-lymphoma-230.jpg
Micrograph showing
follicular lymphoma

An anti-CD37 antibody-radionuclide conjugate provides sustained efficacy and a manageable safety profile in patients with relapsed, CD37+ non-Hodgkin lymphoma (NHL), according to researchers. The drug, 177Lu-DOTA-HH1 (Betalutin), consists of the tumor-specific antibody HH1, which targets the CD37 antigen on the surface of NHL cells, conjugated to the β-emitting isotope lutetium-177... [Read Article]

Print Friendly, PDF & Email

Thiotepa, rituximab improve response in CNS lymphoma

Print Friendly, PDF & Email


ICML_Palazzo_exterior_230.jpg
Palazzo Dei Congressi,
site of 13-ICML

Adding thiotepa and rituximab to the treatment of primary central nervous system (CNS) lymphoma is feasible from a safety perspective and has yielded promising results, according to new research. An analysis of the IELSG 32 trial—in which patients received methotrexate and cytarabine alone, with rituximab, or with rituximab... [Read Article]

Print Friendly, PDF & Email

EZH2 inhibitor proves active in rel/ref NHL

Print Friendly, PDF & Email


FL_cells_240.jpg
Micrograph showing FL

The EZH2 inhibitor tazemetostat (EPZ-6438) has shown “meaningful clinical activity” as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL), according to researchers. In a phase 1 trial, 9 of the 15 evaluable NHL patients achieved an objective response to tazemetostat. This included 2 ongoing complete responses (CRs), 1 in a patient with... [Read Article]

Print Friendly, PDF & Email

Bleomycin can be safely omitted after negative PET2 in HL

Print Friendly, PDF & Email


PET_scanner_Jens_Maus-230.jpg
PET scanner
Photo by Jens Maus

Results of the RATHL trial indicate that bleomycin can be omitted from ABVD therapy following a negative interim FDG-PET scan in patients with Hodgkin lymphoma. Progression-free survival (PFS) and overall survival (OS) were the same at 3 years for patients who were PET-negative after 2 cycles of... [Read Article]

Print Friendly, PDF & Email